Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 trial in patient with ASD

Next Previous
X
Search
Trial Profile

Phase 2 trial in patient with ASD

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AJA 001 (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Dec 2024 New trial record
    • 12 Dec 2024 According to a DeFloria media release, The safety, PK, and PD findings from phase 1 study support doses from 100 mg to 660 mg of AJA001 per day for Phase 2 trials in children, adolescents, and adults with ASD.
    • 12 Dec 2024 According to a DeFloria media release, look forward to initiating two Phase 2 trials of AJA001 in ASD in the second quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top